Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M

Ginkgo Bioworks Holdings, Inc.

2022-Q2 EPS reported -$0.78 revenue$313,023,000

Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.
Biosecurity revenue $100M with 36% gross margin; expects at least $260M for FY 2022.
Adjusted EBITDA improved to -$23M from -$38M YoY; cash balance ~$1.4B.
Pending acquisitions of Zymergen (all-stock) and Bayer's West Sacramento facility expected to close Q4 2022 / Q1 2023.
Dr. Kathy Hopinkah Hannan appointed to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.